Research
Hormonal
Insomnia disorder is an independent risk factor for the development of mental health disorders, including depression, anxiety, and suicide, suggesting that treating insomnia may have preventive value for these conditions.
Treat insomnia seriously not just for sleep quality, but as a critical step in preventing depression and anxiety. Addressing sleep problems early may reduce the risk of developing these mental health conditions.
GoodSupportsHIGH confidence
Insomnia disorder... signifies an important and independent risk factor for physical and, especially, mental health... Recent studies suggest that treatment of insomnia may prove to add significantly as a preventive strategy to combat the global burden of mental disorders.
Why this rating
Based on multiple cited studies (Baglioni, Hertenstein, Pigeon) showing strong associations.
Source
Insomnia disorder: State of the science and challenges for the future
Dieter Riemann et al. · Journal of Sleep Research · 2022
DOI 10.1111/jsr.13604
narrative_reviewCited 312×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Cognitive-behavioral therapy for insomnia (CBT-I) is the first-line treatment for insomnia disorder, with hypnotics recommended only for short-term use when CBT-I is unavailable or ineffective.Strong
- Digital Cognitive-Behavioral Therapy for Insomnia (dCBT-I) is a cost-effective and viable method for delivering CBT-I at scale, potentially reducing healthcare expenditures.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →